Rapport Therapeutics, Inc. (RAPP) Income Statement
19 Followers
Rapport Therapeutics, Inc. Income Statement
Last quarter (Q3 2024), Rapport Therapeutics, Inc.'s total revenue was $―, a decrease of ― from previous quarter. In Q3, Rapport Therapeutics, Inc.'s net income was $-17.54M. See Rapport Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23
Total Revenue
$ ―
Cost of Revenue
$ ―
Gross Profit
$ ―
Operating Expense
$ 36.18M
Operating Income
$ -36.18M
Net Non Operating Interest Income Expense
$ 2.53M
Other Income Expense
$ 1.12M
Pretax Income
$ -34.78M
Tax Provision
$ 10.00K
Earnings From Equity Interest Net Of Tax
$ ―
Net Income Common Stockholders
$ -34.79M
Basic EPS
$ -23.10
Diluted EPS
$ -23.10
Basic Average Shares
$ 1.51M
Diluted Average Shares
$ 1.51M
Dividend Per Share
$ ―
Total Operating Income As Reported
$ ―
Reported Normalized Basic E P S
$ ―
Reported Normalized Diluted E P S
$ ―
Rent Expense Supplemental
$ ―
Total Expenses
$ 36.18M
Net Income From Continuing And Discontinued Operation
$ -34.79M
Normalized Income
$ -25.56M
Interest Expense
$ ―
EBIT
$ -34.78M
EBITDA
$ -34.66M
Currency in USD
Rapport Therapeutics, Inc. Earnings and Revenue History